tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
erlotinib teva b.v. 150 mg
teva b.v., holandsko - erlotinib - 44 - cytostatica
erlotinib teva b.v. 100 mg
teva b.v., holandsko - erlotinib - 44 - cytostatica
erlotinib stada 150 mg
stada arzneimittel ag, nemecko - erlotinib - 44 - cytostatica
erlotinib stada 100 mg
stada arzneimittel ag, nemecko - erlotinib - 44 - cytostatica
erlotinib teva 150 mg filmom obalené tablety
teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica
erlotinib teva 100 mg filmom obalené tablety
teva pharmaceuticals slovakia s.r.o., slovensko - erlotinib - 44 - cytostatica
erlotinib zentiva 150 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica
erlotinib zentiva 100 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica
erlotinib zentiva 25 mg
zentiva, k.s., Česká republika - erlotinib - 44 - cytostatica